Basel, Switzerland, June 22, 2020 – ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in the “NANO” clinical study.
Our CEO Dr. Marija Plodinec explains what ARTIDIS is all about in a very interesting and inspiring conversation with Alec Santiago. Part one: Part two:
Basel, Switzerland, December 5th, 2019 – ARTIDIS AG (“ARTIDIS”), a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds securing early...
Artidis, ein Spin-off der Universität Basel, wurde in die internationale Kohorte für Medizinprodukte 2019 des Texas Medical Center (TMC) Innovation Institute aufgenommen. Damit ist das Unternehmen in das grösste medizinische Zentrum der Welt eingebettet.
Basel, Switzerland, November 18th, 2019 – ARTIDIS announces its successful integration in the highly competitive international Medical Device Cohort 2019 of the Texas Medical Center’s (TMC) Innovation Institute.